Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

U.S. and China regulators have now cleared Sineugene Therapeutics' ALS gene therapy SNUG01 for clinical trials.

Bar-Ilan University has joined a major new €8 million European initiative aimed at revolutionizing how personalized cancer ...

An expert discusses how gene therapy represents a breakthrough treatment approach for BCG-unresponsive patients, offering ...

Elevidys is the first gene therapy approved in the U.S. for Duchenne’s muscular ... in 2023 for a narrow range of young patients and was expanded last year for use in older patients, including those ...

One of Sam Altman’s pet projects aims to engineer the brain to better work with brain-computer interface implants.

Sarepta Therapeutics is still assessing how best to prevent liver injury from its commercialized Duchenne muscular dystrophy gene therapy. But Sarepta partner Hansa Biopharma has encouraging ...

A team of scientists at the National Institutes of Health (NIH) used gene editing to fix the mutation that causes a form of the rare Tay-Sachs disease in mice, sparking hope that the approach could ...

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not ...

Heart diseases are still the number one cause of death worldwide. But scientists are trying to change that... | Genetics And ...

Many gene therapy developers use viral vectors that exhibit specific tissue tropism as delivery vehicles, meaning they preferentially infect certain tissues to deliver the gene therapy cargo.

The tremendous raise comes amid what has been a tough time for biotechs, and particularly gene therapy. Let's Talk Money: ...